...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pain research & management: the journal of the Canadian Pain Society = journal de la socie?te? canadienne pour le traitement de la douleur >Effect of Preoperative Zoledronic Acid Administration on Pain Intensity after Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fractures
【24h】

Effect of Preoperative Zoledronic Acid Administration on Pain Intensity after Percutaneous Vertebroplasty for Osteoporotic Vertebral Compression Fractures

机译：术前唑酸酸施氮对骨质疏松椎体压缩骨折经皮椎体成形术后疼痛强度的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction. This study aimed to compare and analyze the effect of preoperative zoledronic acid (ZOL) administration on pain intensity after percutaneous vertebroplasty (PVP) for osteoporotic vertebral compression fracture (OVCF). Methods . The study included 242 patients with OVCFs who underwent PVP in our hospital between January 2015 and June 2018. The patients were randomly assigned to either a ZOL group ( n =?121) or a control group ( n =?121). The patients in the ZOL group were treated preoperatively with intravenous infusion of 5 mg ZOL. Those in the control group were treated without ZOL. All the patients were followed up for 1 year. Results . No statistically significant differences in age, sex, weight, and body mass index (BMI) were found between the two groups. During the follow-up period, the visual analog scale score and Oswestry dysfunction index score in the ZOL group were lower than those in the control group. The bone mineral density at 6 or 12 months after treatment was significantly higher and the levels of the bone metabolism markers were significantly lower in the ZOL group than in the control group ( P 0.05 for both). Two patients in the treatment group had new vertebral fractures, whereas 13 patients in the control group had new vertebral fractures, which translate to recompression vertebral fracture incidence rates of 1.7% and 10.7%, respectively. The incidence rate of mild adverse reactions was significantly higher in the ZOL group than in the control group, but all the cases were endurable. Conclusion . Intravenous infusion of ZOL before PVP can effectively reduce postoperative pain intensity, reduce bone loss, increase bone density, reduce the risk of refracture, and improve patient quality of life.
机译：介绍。本研究旨在比较和分析术前唑醇（ZOL）给予骨盆椎体压缩骨折（PVP）后术前唑醇（ZOL）给药对骨质疏松椎体压缩骨折（OVCF）的疼痛强度的影响。方法 。该研究包括242例OVCF患者，在2015年1月至2018年1月期间接受过PVP。患者被随机分配给ZOL基团（n =Δ121）或对照组（n =Δ121）。 ZOL组中的患者术前静脉输注5mg ZOL治疗。对照组的那些在没有ZOL的情况下治疗。所有患者都随访1年。结果 。两组之间发现了年龄，性别，重量和体重指数（BMI）的统计学意义差异。在随访期间，ZOL组的视觉模拟比分和Oswestry功能障碍指数得分低于对照组中的评分。治疗后6或12个月的骨矿物密度显着升高，ZOL组在ZOL组中骨代谢标志物的水平显着低于对照组（两者对照组）。治疗组中的两名患者有新的椎骨骨折，而13例对照组患者具有新的椎体骨折，其转化为12％和10.7％的重新压缩椎骨裂缝发生率。 ZOL组在对照组中显着高度不良反应的发生率显着较高，但所有病例均持续。结论 。 PVP静脉内输注ZOL可以有效降低术后疼痛强度，降低骨质损失，增加骨密度，降低折射风险，提高患者的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号